Cisplatin Dosing and Management
For cisplatin administration, use aggressive IV hydration (1-2 liters pre-treatment over 8-12 hours, then 2 liters with 37.5g mannitol over 6-8 hours during infusion), add magnesium supplementation (8-16 mEq), and ensure adequate renal function (serum creatinine <1.5 mg/dL) before each cycle. 1
Standard Dosing Schedules
The FDA-approved dosing varies by indication 1:
- Testicular cancer: 20 mg/m² IV daily × 5 days per cycle (in combination regimens)
- Ovarian cancer: 75-100 mg/m² IV once every 4 weeks (with cyclophosphamide) OR 100 mg/m² as single agent every 4 weeks
- Bladder cancer: 50-70 mg/m² IV every 3-4 weeks (50 mg/m² for heavily pretreated patients)
For intraperitoneal administration in optimally debulked ovarian cancer: 75-100 mg/m² IP on day 2 (following IV paclitaxel), every 3 weeks for 6 cycles 2. The lower dose of 75 mg/m² may reduce toxicity, though efficacy at this dose versus 100 mg/m² remains unclear 2.
Hydration Protocol
The FDA label mandates specific hydration 1:
- Pre-treatment: 1-2 liters IV fluid over 8-12 hours before cisplatin
- During infusion: Dilute cisplatin in 2 liters of 5% dextrose in ½ or ⅓ normal saline containing 37.5g mannitol; infuse over 6-8 hours
- Post-treatment: Maintain adequate hydration and urinary output for 24 hours
Critical caveat: Do NOT dilute cisplatin in 5% dextrose alone 1.
Emerging evidence supports shorter hydration regimens 3, 4, 5. Short-duration, low-volume outpatient hydration appears safe even for intermediate-to-high dose cisplatin 3. One study of 467 patients showed significantly lower nephrotoxicity with short hydration (14.4% creatinine increase ≥grade 1) versus conventional hydration (33.1%) 4. For elderly patients specifically, short-duration/low-volume hydration may be preferable given hemodynamic concerns 6.
Anti-Emetic Protocol
While the evidence provided doesn't detail specific anti-emetic regimens, cisplatin is highly emetogenic. Standard practice requires:
- 5-HT3 antagonist + NK1 antagonist + dexamethasone (based on general oncology knowledge)
- Anticipatory anti-emetics for subsequent cycles
Monitoring Parameters
Before each cycle, verify 1:
- Renal function: Serum creatinine <1.5 mg/dL AND/OR BUN <25 mg/dL
- Hematologic recovery: Platelets ≥100,000/mm³, WBC ≥4,000/mm³
- Audiometry: Auditory acuity within normal limits
- Monitor for myelosuppression, dehydration, electrolyte loss
- Assess end-organ toxicities (renal, hepatic)
- Patients often require IV fluids for 5-7 days post-chemotherapy in outpatient setting to prevent/treat dehydration 2
For IP cisplatin specifically: Patients must have normal renal function at baseline, appropriate performance status, and no pre-existing neuropathy 2, 7, 2.
Magnesium Supplementation
Add magnesium 8-16 mEq to the hydration regimen 3, 5. Multiple studies demonstrate magnesium supplementation limits cisplatin-induced nephrotoxicity 3, 5. This is particularly important as hypomagnesemia commonly occurs with cisplatin.
Mannitol Forced Diuresis
Include 37.5g mannitol in the infusion solution 1. Four of seven studies found protective effects of adding mannitol 5. Consider mannitol especially for high-dose cisplatin and/or patients with pre-existing hypertension 3.
Management of Renal Impairment
For patients with borderline renal function or minimal dysfunction, consider split-dose cisplatin administration: 35 mg/m² on days 1 and 2, or days 1 and 8 (Category 2B) 8, 9. However, the relative efficacy of this modification remains undefined 8.
Estimate GFR to assess cisplatin eligibility 8. For patients with eGFR <60 mL/min, dose reductions are necessary 10. Using the abbreviated MDRD formula with an intermediary dose reduction level for eGFR 50-59.9 mL/min may allow higher cumulative cisplatin doses without increased toxicity 10.
Critical threshold: Pretreatment eGFR is the strongest predictor of post-cisplatin chronic kidney disease 11. Patients with lower baseline eGFR face highest CKD risk 11. Cisplatin causes a mean eGFR decrease of 8.1 mL/min/1.73 m² 11.
For cisplatin-ineligible patients (significant renal impairment or comorbidities): No data support perioperative chemotherapy 8, 9. Consider carboplatin-based regimens instead, though carboplatin should NOT be substituted for cisplatin in the perioperative/curative setting 8, 9. For metastatic disease, gemcitabine/carboplatin is an acceptable alternative 8.
Long-Term Renal Consequences
Reduced eGFR (<90 mL/min/1.73 m²) occurs in 41% of testicular cancer survivors and associates with 12:
- 2-20 fold increased odds of hypertension (depending on severity)
- 6-fold increased odds of hyperlipidemia (eGFR 30-44)
- 7-fold increased odds of cardiovascular disease (eGFR 30-44)
The eGFR reduction is dose-dependent and correlates with cumulative cisplatin exposure 12.
Special Populations
Elderly patients face significantly higher rates of cisplatin-induced nephrotoxicity and AKI 6. Contributing factors include renal hypoperfusion, increased comorbidities (CKD, cardiovascular disease, diabetes), concomitant nephrotoxic medications (NSAIDs, ACE inhibitors/ARBs, antibiotics), and decreased cisplatin clearance 6. For elderly patients requiring high-dose cisplatin (100 mg/m²), consider using a less nephrotoxic platinum agent 6.
Administration Precautions
- Never use aluminum-containing needles or IV sets - aluminum reacts with cisplatin causing precipitation and potency loss 1
- Administer by slow IV infusion over 6-8 hours - never rapid IV injection 1
- Wear impervious gloves when handling 1
- Verify dose does not exceed 100 mg/m² per cycle - pharmacists should contact prescriber if dose exceeds this 1
Hypersensitivity Risk
Anaphylactic-like reactions can occur, especially with repeat platinum exposure 7, 1. Have emergency equipment and medications (epinephrine, corticosteroids, antihistamines) immediately available 1. Reactions manifest as facial edema, wheezing, tachycardia, and hypotension within minutes of administration 1.